Insights provided by DeciBio, a strategy consultancy focused on the life science and biopharma industry.

‍

Highlights & Summary

As we enter H2, the next-gen therapeutics space is buzzing from regulatory milestones in cell therapy, including the first CAR-T therapy approved for a solid tumor, to clinical trial progress across gene therapy and a record-setting biotech IPO in the ADC-adjacent space.

Happy Reading!

‍

‍

Cell Therapy

Satri-cel becomes the world’s first CAR-T therapy for a solid tumor | Regulatory

China's NMPA approved CARsgen Therapeutics' satri-cel (satricabtagene autoleucel), an autologous Claudin18.2-directed CAR-T therapy, for patients with Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma who have failed at least two prior lines of therapy. The clearance makes satri-cel the first CAR-T product approved anywhere for a solid tumor.  

Obe-cel CAR-T therapy show drug-free remissions in lupus and rheumatoid arthritis at EULAR 2026 | Clinical Trial

New data at the EULAR 2026 Annual Meeting showed autologous CD19 CAR-T therapies driving drug-free remissions in patients with refractory rheumatic disease. The phase 1 CARLYSLE study tested obecabtagene autoleucel (obe-cel) in severe refractory systemic lupus erythematosus and reported responses with no ICANS and no significant cytokine release syndrome.

Cartesian licenses WestGene LNP tech to build in vivo BCMA CAR-T platform for autoimmune disease | Partnership

Cartesian Therapeutics entered a licensing agreement with WestGene Biopharma to develop an in vivo CAR-T platform for autoimmune diseases, pairing WestGene's targeted lipid nanoparticle delivery with the mRNA payload from Cartesian's clinically validated Descartes-08 program. The companies plan to initiate a clinical trial in myasthenia gravis in the second half of 2026 using an mRNA-encoded, BCMA-directed construct, with initial clinical data anticipated in the first half of 2027.

Cellectis secures FDA RMAT designation for allogeneic CD22 CAR-T lasme-cel in relapsed/refractory B-ALL | Regulatory

The FDA granted Regenerative Medicine Advanced Therapy designation to Cellectis' lasme-cel (lasmecabtagene timgedleucel), a CD22-targeting allogeneic CAR-T candidate, for relapsed or refractory B-cell acute lymphoblastic leukemia. Cellectis positioned lasme-cel as the first allogeneic CAR-T therapy in a pivotal trial to receive RMAT, with interim data from the pivotal phase 2 study expected in the fourth quarter of 2026.

Cellares to automate manufacturing of TScan's TSC-101 TCR-T therapy on Cell Shuttle platform | Manufacturing

Cellares and TScan Therapeutics signed an agreement to move manufacturing of TSC-101, TScan's donor-derived TCR-T therapy for residual disease and relapse prevention in AML and MDS patients undergoing allogeneic hematopoietic cell transplant, onto Cellares' fully automated Cell Shuttle production platform and Cell Q quality control system. The closed, automated workflow is intended to cut process variability and labor intensity as TScan advances TSC-101 toward a pivotal trial expected to begin in the second quarter of 2026.

‍

‍

‍

Gene Therapy

4DMT completes global Phase 3 enrollment for 4D-150 in wet AMD | Clinical Trial
4D Molecular Therapeutics completed enrollment in 4FRONT-2, its second Phase 3 trial of 4D-150 in wet AMD, about four months ahead of initial projections and with more than 500 patients expected. The global study will assess non-inferiority in visual acuity and reduction in aflibercept injection burden, with 52-week topline data expected in the second half of 2027.

REGENXBIO completes confirmatory dosing for DMD asset | Clinical Trial
REGENXBIO completed dosing in the confirmatory study of RGX-202 for Duchenne muscular dystrophy, supporting a planned BLA submission under the accelerated approval pathway in Q3 2026. The submission is expected to include safety data from 63 patients and pivotal efficacy data from 30 patients, following prior results showing strong microdystrophin expression and early functional benefit.

REGENXBIO aligns with FDA on Hunter syndrome gene therapy path | Regulatory
REGENXBIO said the FDA agreed that existing clinical data for NAVSUNLI, its one-time gene therapy for Hunter syndrome, may be sufficient for consideration under the accelerated approval pathway. The company plans a Type A meeting in July and expects to resubmit the BLA in Q3 2026 without enrolling additional patients or conducting a new untreated-control study.

Taysha completes pivotal dosing for TSHA-102 in Rett syndrome | Clinical Trial
Taysha Gene Therapies completed dosing in the REVEAL pivotal trial of TSHA-102 for Rett syndrome and reported longer-term Phase 1/2 data showing durable functional gains across 12 treated patients. The company expects six-month interim pivotal data and FDA feedback on a potential BLA pathway in the first half of 2027.

uniQure says FDA accepts AMT-130 data for Huntington’s BLA | Regulatory
uniQure said the FDA indicated that three-year Phase 1/2 data for AMT-130 may serve as the primary basis for an accelerated approval BLA in Huntington’s disease. The company plans to submit the application in Q3 2026 while aligning with the agency on the design of a confirmatory study.

‍

‍

‍

Oligo

Novartis' del-brax hits primary endpoint in FSHD trial | Clinical Trial

The biomarker cohort of the Phase 1/2 FORTITUDE study met its primary and key secondary endpoints, with reductions in KHDC1L and creatine kinase indicating target engagement and reduced muscle damage in facioscapulohumeral muscular dystrophy patients. Del-brax is an antibody oligonucleotide conjugate targeting DUX4 expression, gained through Novartis' acquisition of Avidity Biosciences, and now has a confirmatory Phase 3 trial enrolling.

Argo Biopharma reports HAE attack reduction with siRNA BW-20805 | Clinical Trial

Across 18 dosed patients, time-normalized HAE attack rate was reduced by 99% in the 600 mg Q24W group (83% attack-free), 93% in 300 mg Q24W, and 95% in 300 mg Q12W, with plasma prekallikrein reductions exceeding 90% through Day 169 across all groups. No drug-related serious adverse events were reported; the most common AE was mild, transient injection-site reaction.

Oak Hill Bio raises $32.5M to push Angelman syndrome ASO into Phase 3 | Financing

The $32.5 million Series A, co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors, will advance rugonersen, an ASO targeting the UBE3A-ATS transcript, into a Phase 3 study in Angelman syndrome in mid-2026. Dicerna founder Doug Fambrough joined the board as part of the round.

ProQR raises $59M and posts human data for RNA-editing oligonucleotide | Financing

ProQR priced a $50 million registered direct offering, with Eli Lilly concurrently buying $9.2 million in shares to maintain its pro rata stake. The same day, ProQR reported Phase 1 data for AX-0810 showing up to an 8-fold increase in serum bile acids in the 6 mg/kg cohort and an eight-week half-life, with no serious adverse events.

ST Pharm expands RNA CDMO platform into mRNA-LNP | Manufacturing

At BIO USA 2026, ST Pharm detailed an expanded integrated RNA CDMO platform now spanning oligonucleotides, mRNA-LNP, guide RNA, and monomer manufacturing. The company cited antibody-oligonucleotide conjugates as a key focus area, since the AOC payload is ultimately an siRNA, ASO, or PMO requiring high-purity synthesis and impurity control.

‍

‍

‍

‍

‍

ADCs

First Bispecific ADC Approval | Regulatory

Sichuan Biokin received China NMPA approval for iza-bren, an EGFR×HER3 bispecific ADC, for recurrent or metastatic nasopharyngeal carcinoma following prior platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy. The approval marks the first regulatory approval for a bispecific ADC globally and was supported by Phase III data showing a confirmed ORR of 54.6% versus 27.0% for chemotherapy, with improved PFS

Parabilis Raises $670M in Record Biotech IPO | Financing

Parabilis Medicines, formerly FogPharma, raised $670M in an upsized Nasdaq IPO, with shares rising ~58% on the first day of trading. While not a traditional ADC company, Parabilis is relevant to next-gen conjugates through its Helicon platform and Regeneron-partnered Antibody-Helicon Conjugates (AHCs), which pair antibody-guided delivery with Helicon peptide payloads designed to engage historically “undruggable” intracellular targets.  

ADC Therapeutics Announces Strategic Reorganization | Personnel

ADC Therapeutics announced a strategic reorganization, including a planned ~17% workforce reduction expected to generate ~$10M in annualized cost savings. The move follows heightened scrutiny around Zynlonta after LOTIS-5 met its Phase III PFS endpoint but showed a higher rate of Grade 5 treatment-emergent adverse events in the Zynlonta-plus-rituximab arm.

Sigvotatug vedotin misses OS end point, Phase III Trial | Clinical Trial

Pfizer reported that sigvotatug vedotin, an investigational IB6-directed ADC acquired through the Seagen transaction, did not significantly improve overall survival versus docetaxel in the Phase III SigVie-002 trial in previously treated, advanced nonsquamous NSCLC.  

Veraxa Biotech Begins Nasdaq Trading | Financing

Veraxa Biotech began trading on Nasdaq under the ticker VRXA following its business combination with Voyager Acquisition Corp. The company is developing next-generation antibody-based oncology therapeutics, including bispecific T-cell engagers and ADCs, supported by its BiTAC platform designed to improve tumor selectivity through dual-antigen targeting.